menu
    • menu

    Company profile for Polaryx Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Polaryx® Therapeutics, Inc is developing patient-friendly, orally-available, small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Polaryx’s® drugs enhance cellular clearance pathways to eliminate cellular waste.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Polaryx TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    South Tower, 140 E Ridgewood Ave Suite 415, Paramus, NJ 07652, United States
    Telephone
    Telephone
    +1-201-940-7236
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.polaryx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Polaryx777

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Polaryx Announces FDA Grants Orphan Drug Designation for PLX-200
    Polaryx Announces FDA Grants Orphan Drug Designation for PLX-200

    30 Aug 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-announces-fda-grants-orphan-drug-designation-for-plx-200-in-gm2-gangliosidoses-301364861.html

    PRNEWSWIRE
    30 Aug 2021
    Share Share
    Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug
    Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug

    11 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-krabbe-disease-with-plx-300-301226528.html

    PRNEWSWIRE
    11 Feb 2021
    Share Share
    Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan
    Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan

    10 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-krabbe-disease-with-plx-300-301226528.html

    PRNEWSWIRE
    10 Feb 2021
    Share Share
    Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations
    Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations

    18 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-niemann-pick-disease-types-a-and-b-with-plx-300-301195771.html

    PRNEWSWIRE
    18 Dec 2020
    Share Share
    Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations
    Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations

    18 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-niemann-pick-disease-types-a-and-b-with-plx-300-301195771.html

    PRNEWSWIRE
    18 Dec 2020
    Share Share
    Polaryx Receives Both Rare Pediatric Disease and ODD
    Polaryx Receives Both Rare Pediatric Disease and ODD

    25 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/polaryx-therapeutics-receives-both-rare-pediatric-disease-and-orphan-drug-designations-for-the-treatment-of-gm2-gangliosidosis-with-plx-300-301180296.html

    PRNEWSWIRE
    25 Nov 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search